Axsome Therapeutics Inc.

Biopharma Axsome Therapeutics develops CNS therapies, with approved products Auvelity, Sunosi, Symbravo and a pipeline of Phase III candidates AXS‑05 (Alzheimer’s agitation), AXS‑07 (migraine), AXS‑12 (narcolepsy) and AXS‑14 (fibromyalgia).

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Manufacturing
Industry: Pharmaceutical Manufacturing

Employees: 816
HQ: New York

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
AXSM	Axsome Therapeutics Inc. Cap: 8.7B	EQUITY	NMS	USD	US05464T1043	Active	📈